<DOC>
	<DOCNO>NCT00266123</DOCNO>
	<brief_summary>To demonstrate superiority SRL + TAC elimination + corticosteroid ( Group I ) SRL + MMF + corticosteroid ( Group II ) TAC + MMF + corticosteroid ( Group III ) respect renal allograft function month 12 post-transplantation .</brief_summary>
	<brief_title>Study Comparing Two Sirolimus Regimens vs. Tacrolimus Mycophenolate Mofetil Regimen Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Age &gt; 18 year . Endstage renal disease subject schedule receive primary secondary renal allograft cadaveric donor , livingunrelated mismatch donor , livingrelated mismatch donor . Unreported HLA value consider match . Women childbearing potential must negative serum pregnancy test administration assign treatment agree use medically acceptable method contraception throughout treatment period 3 month follow discontinuation assign treatment . Other inclusion apply . Evidence active systemic localize major infection . Known hypersensitivity SRL derivative , macrolide antibiotic , corticosteroid , TAC MMF . Multiple organ transplant ( i.e. , prior concurrent transplantation organs renal transplant ) . Other exclusion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Kidney Failure</keyword>
	<keyword>Kidney Transplant</keyword>
</DOC>